Aliada Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 20

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.4B

Aliada Therapeutics General Information

Description

Developer of drug development therapy designed to treat central nervous system diseases. The company applies its novel technology to specific central nervous system target antibody binders and progress programs through preclinical evaluation, enabling medical professionals to treat central nervous system diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 501 Boylston Street
  • 9th Floor
  • Boston, MA 02116
  • United States
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Drug Discovery
Acquirer
Vertical(s)
Corporate Office
  • 501 Boylston Street
  • 9th Floor
  • Boston, MA 02116
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aliada Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 11-Dec-2024 $1.4B Completed Generating Revenue
3. Early Stage VC 30-Dec-2022 Completed Generating Revenue
2. Early Stage VC 06-Jul-2021 $1M $21M Completed Startup
1. Seed Round $20M $20M Completed Startup
To view Aliada Therapeutics’s complete valuation and funding history, request access »

Aliada Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-1
Seed
To view Aliada Therapeutics’s complete cap table history, request access »

Aliada Therapeutics Patents

Aliada Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021253821-A1 Anti-cd98 antibodies and uses thereof Pending 08-Apr-2020
CA-3179922-A1 Anti-cd98 antibodies and uses thereof Pending 08-Apr-2020
EP-4132974-A1 Anti-cd98 antibodies and uses thereof Pending 08-Apr-2020
EP-4132974-A4 Anti-cd98 antibodies and uses thereof Pending 08-Apr-2020
US-20230174669-A1 Anti-cd98 antibodies and uses thereof Pending 08-Apr-2020 C07K16/2896
To view Aliada Therapeutics’s complete patent history, request access »

Aliada Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aliada Therapeutics Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Johnson & Johnson JJDC Corporate Venture Capital Minority
OrbiMed Growth/Expansion Minority
RA Capital Management Asset Manager Minority
Sanofi Ventures Corporate Venture Capital Minority
To view Aliada Therapeutics’s complete investors history, request access »

Aliada Therapeutics FAQs

  • When was Aliada Therapeutics founded?

    Aliada Therapeutics was founded in 2021.

  • Where is Aliada Therapeutics headquartered?

    Aliada Therapeutics is headquartered in Boston, MA.

  • What is the size of Aliada Therapeutics?

    Aliada Therapeutics has 20 total employees.

  • What industry is Aliada Therapeutics in?

    Aliada Therapeutics’s primary industry is Discovery Tools (Healthcare).

  • Is Aliada Therapeutics a private or public company?

    Aliada Therapeutics is a Private company.

  • What is the current valuation of Aliada Therapeutics?

    The current valuation of Aliada Therapeutics is .

  • What is Aliada Therapeutics’s current revenue?

    The current revenue for Aliada Therapeutics is .

  • How much funding has Aliada Therapeutics raised over time?

    Aliada Therapeutics has raised $53M.

  • Who are Aliada Therapeutics’s investors?

    Johnson & Johnson JJDC, OrbiMed, RA Capital Management, and Sanofi Ventures have invested in Aliada Therapeutics.

  • When was Aliada Therapeutics acquired?

    Aliada Therapeutics was acquired on 11-Dec-2024.

  • Who acquired Aliada Therapeutics?

    Aliada Therapeutics was acquired by AbbVie.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process